Russell Investments Group, Ltd. Relay Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

$69.8 Billion
Q4 2024

A detailed history of Russell Investments Group, Ltd. transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 79,804 shares of RLAY stock, worth $270,535. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,804

Previous 11,245 609.68%

Holding current value

$270,535

Previous $79,000 315.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$4.12 - $6.8 $282,463 - $466,201	68,559 Added 609.68%	79,804 $328,000
Q3 2024 Nov 13, 2024	SELL	$6.23 - $9.51 $50,973 - $77,810	-8,182 Reduced 42.12%	11,245 $79,000
Q2 2024 Aug 08, 2024	SELL	$5.9 - $8.02 $947,215 - $1.29 Million	-160,545 Reduced 89.21%	19,427 $126,000
Q1 2024 May 08, 2024	BUY	$7.5 - $12.07 $491,130 - $790,391	65,484 Added 57.2%	179,972 $1.49 Million
Q4 2023 Feb 05, 2024	BUY	$6.01 - $11.48 $651,213 - $1.24 Million	108,355 Added 1766.75%	114,488 $1.26 Million
Q3 2023 Nov 13, 2023	BUY	$8.24 - $12.97 $24,991 - $39,338	3,033 Added 97.84%	6,133 $51,000
Q2 2023 Aug 10, 2023	BUY	$9.99 - $18.27 $30,969 - $56,637	3,100 New	3,100 $38,000
Q1 2022 May 05, 2022	SELL	$20.26 - $32.36 $17,646 - $28,185	-871 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$29.75 - $37.99 $25,912 - $33,089	871 New	871 $27,000
Q2 2021 Aug 04, 2021	SELL	$27.5 - $38.19 $828,685 - $1.15 Million	-30,134 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$32.52 - $61.53 $979,957 - $1.85 Million	30,134 New	30,134 $1.04 Million

Others Institutions Holding RLAY

# of Institutions

207

Shares Held

159M

Call Options Held

100K

Put Options Held

26.8K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $408M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Relay Therapeutics, Inc. Transaction History